Core Insights - electroCore reported record net sales of $32.0 million for the full year 2025, representing a 27% increase from $25.2 million in 2024, driven by a 25% growth in the U.S. prescription business and a 97% increase in general wellness sales [1][2][7] Financial Performance - The increase in net sales of $6.8 million was primarily due to higher sales of prescription products gammaCore and Quell Fibromyalgia in the U.S., as well as Truvaga handsets in the general wellness channel [2] - Gross profit rose by $6.4 million to $27.8 million in 2025, with a gross margin of 87%, up from 85% in 2024 [3] - Research and development expenses increased to $2.7 million, up by $0.4 million from the previous year, mainly due to development costs for gammaCore Emerald and a new mobile application [4] - Selling, general, and administrative expenses totaled $38.2 million, an increase of $7.0 million from $31.2 million in 2024, driven by higher sales and marketing costs [5] - Total operating expenses for 2025 were approximately $40.9 million, compared to $33.6 million in 2024 [6] Loss and Cash Position - The GAAP net loss for 2025 was $14.0 million, compared to a loss of $11.9 million in 2024, with a net loss per share of $1.65 [9][21] - Total cash, cash equivalents, and marketable securities amounted to $11.6 million at the end of 2025, down from $12.2 million at the end of 2024 [11] Future Guidance - The company provided revenue guidance for 2026, anticipating approximately 30% annual growth over 2025 [12] Organizational Changes - Dan Goldberger, the CEO, will retire effective April 1, 2026, with Joshua Lev taking on the role of interim President and CFO, and Michael Fox joining as Chief Operating Officer [13][14]

Core Insights - electroCore, Inc. has partnered with former NFL player Greg Buttle to promote its Truvaga™ Plus device, which is designed for vagus nerve stimulation to enhance relaxation, clarity, and sleep quality [1][4] - Truvaga Plus is a handheld device that utilizes bioelectronic technology to stimulate the vagus nerve, helping users transition from stress to a balanced state [3][8] - The partnership will include radio spots and digital campaigns aimed at raising awareness about stress management and the benefits of Truvaga Plus [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive technologies [6] - The company offers products like gammaCore and Quell, which treat chronic pain, alongside Truvaga and TAC-STIM for general wellness [6] - Truvaga Plus is backed by over 20 years of research in bioelectronic medicine and is intended for general health and wellness purposes [5][8]